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Abstract
Background: During the pre-patent stage of infection, juvenile Schistosoma blood flukes co-opt signals from the
adaptive immune system to facilitate parasite development, but the types of responses that are induced at this
early stage of infection, and the parasite antigens they target, have not been characterized.
Results: Through analysis of experimental pre-patent infections, we show that the S. mansoni cysteine protease
SmCB1 is rapidly targeted by an antigen-specific IgE response. The induction of this response is independent of
schistosome eggs as infection with male or female worms alone also induced SmCB1-specific IgE. We also show
that the SmCB1-specific IgE response is dependent on cognate CD4
+ T cell help and IL-4, suggesting that pre-
patent Th2 responses provide T cell help for the SmCB1-specific IgE response. Finally, exposed human subjects also
produced IgE against SmCB1.
Conclusions: Our data demonstrate that, like eggs, schistosome worms also induce functional type 2 responses
and that a parasite cysteine protease is an inducer of type 2 responses during the early stages of schistosome
infection.
Background
Despite their large size and complex multicellular struc-
ture, schistosomes display a remarkable ability to survive
for years within the mammalian bloodstream, remaining
viable and reproductively active in the face of potentially
damaging immune responses. Mechanisms proposed to
account for the ability of schistosomes to evade immune
destruction include, for example, molecular “camou-
flage”, achieved by adsorption of host molecules to the
parasite surface; molecular “mimicry”, through expres-
sing antigens with amino acid sequences that are similar
or identical to host proteins; continuous surface mem-
brane turn-over; and modulation of immune responses
so that potentially harmful effector mechanisms are
downregulated or inhibited [1].
While schistosomes mostly evade immune injury dur-
ing natural infection, acquired immunity to schistosome
worms that interferes with infection can be demon-
strated under some circumstances, both in naturally
exposed human subjects [2] and laboratory animal mod-
els of vaccine-induced immunity [3]. Although the pre-
cise mechanisms by which protection is mediated under
these different circumstances are debated [2], there is
consensus that protective immunity is dependent on
CD4
+ T cell responses [2]. Intriguingly, there is also evi-
dence that Schistosoma blood flukes exploit CD4
+ Tc e l l
responses, by co-opting the activities of CD4
+ Tc e l l s
during pre-patent infection to promote parasite develop-
ment and subsequent reproduction [4,5]. The mechan-
isms by which CD4
+ T cells facilitate schistosome
development have yet to be fully elucidated, but these
findings suggest that extensive co-evolution has resulted
in a host-parasite relationship where schistosomes
induce CD4
+ T cell responses that are conducive to
establishment of infection, while simultaneously avoid-
ing immune injury. An understanding of the CD4
+ T
cell responses induced by schistosome worms during
pre-patent infection is therefore a prerequisite to
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and establish productive infections.
Unlike the response to schistosome eggs [6], the CD4
+
T cell responses induced by schistosome worms, espe-
cially during normal permissive infection, have not been
extensively characterized. Schistosome eggs are potent
inducers of Th2 responses [7], and some of the major
immunodominant antigens of eggs have been identified
[8-10]. Indeed, an egg-secreted ribonuclease, omega-1,
was recently identified as the principle component of
eggs that conditions dendritic cells for Th2 polarization
[11,12]. In contrast, the CD4
+ T cell response to schisto-
some worms during the pre-patent phase of infection
has been characterized as a Th1 response [13]. Recently
we demonstrated that pre-patent schistosome infection
and infections with either male or female worms alone
that preclude the possibility of egg production, also
induce type 2 responses, characterized by induction of
CD4
+ T cells and basophils that produce IL-4 in
response to worm antigens [14]. Thus the immune
response to developing schistosome worms during pri-
mary infection is more complex than previously appre-
ciated and there is likely much still to learn about the
immunological context within which primary schisto-
some infection is established. For example, the worm
antigens that are the main targets of pre-patent
responses have yet to be described. Specific worm anti-
gens have been identified in the context of immune
resistance, such as in vaccinated animals [15-17] and
putatively resistant human subjects [18-20], but the sig-
nificance of these antigens during normal permissive
infection has not been explored.
In this study, we attempted to identify worm antigens
that stimulate CD4
+ T cell responses during permissive
primary infection, as these antigens may be involved in
stimulating responses that facilitate schistosome worm
development. Because CD4
+ T cell responses to indivi-
dual antigens are difficult to detect directly in mice,
owing to the low frequency of CD4
+ T cells with specifi-
city for any single antigen [21], we used isotype class-
switching of antibody responses as a marker for CD4
+ T
cell responses, since antibody isotype-switching by B cells
requires cognate CD4
+ T cell help [22]. Our results reveal
that the parasite gut-associated S. mansoni cysteine pro-
tease cathepsin B1 (SmCB1; Sm31) [23] is an immunodo-
minant target of adaptive responses during pre-patent
infection, demonstrating that the pre-patent response to
schistosome worms is focused and specific, and is not
simply characterized by immunosuppression or nonspe-
cific polyclonal responses. Further analysis of the pre-
patent response demonstrated the rapid establishment of
an antigen-specific IgE response to SmCB1, which was
dependent on T cell help and IL-4 but independent of
schistosome eggs. Analysis of human subjects who reside
in endemic areas suggests that SmCB1 is also the target
of IgE responses in humans. Together our data suggest
that, like schistosome eggs, schistosome worms also
induce type 2 responses and that a worm cysteine pro-
tease is involved in type 2 response induction.
Results
Immunodominant worm antigens targeted by adaptive
responses during pre-patent infection
To identify the earliest evidence of class-switching in the
humoral response to worm antigens during pre-patent
infection, ELISAs using plate-bound soluble worm anti-
gen (SWAP) were used to detect SWAP-specific IgM,
IgG1 and IgG2b in plasma of infected mice at 0, 1, 2, 3, 4
and 8 weeks post infection (Figure 1 A-C). The first sig-
nificant production of non-IgM antibodies with specifi-
city for worm antigens was detected at 4 weeks post
infection, when SWAP-specific IgG1 was detected (Fig-
ure 1B). To identify the worm antigens targeted by this
IgG1 response during primary schistosome infection, a
SWAP preparation was probed by immunoblot, using
plasma from mice that were infected for 2, 3, 4 or 5
weeks. Bound antibodies were detected with enzyme-
conjugated secondary antibodies specific for murine IgM,
IgG1, and IgG2b and total mouse IgG. Results obtained
with anti-IgG1 are presented in Figure 1. Similar results
were obtained with anti-IgM and pan-specific anti-IgG
secondary antibodies (data not shown). Using anti-IgG1,
no reactivity was detected at 2 weeks (Figure 1D) and 3
weeks (Figure 1E) post infection, but intense reactivity
with an apparent single species of approximately 31 kDa
molecular mass was evident by 4 weeks post infection
(Figure 1F). In concordance with this result, the presence
of worm antigen-specific IgG1 was also first detected at 4
weeks post infection using a whole worm antigen-based
ELISA (Figure 1B). By 5 weeks post infection (Figure 1G),
weak reactivity with additional species of approximately
42 and 64 kDa was also evident, in addition to the 31
kDa species. Thus, the humoral response during a pri-
mary, pre-patent schistosome infection predominantly
targets a worm antigen or antigens of approximately 31
kDa. Furthermore, the production of antigen-specific IgG
suggests this antigen is also the target of a CD4
+ T helper
response, because isotype class-switching by B cells to
production of isotypes other than IgM requires cognate
CD4
+ T cell help, in the form of cytokines and CD40-
CD40L interactions [22].
SmCB1 is the target of an IgE response during pre-patent
schistosome infection
Previous studies have shown that the S. mansoni gut pro-
tease cathepsin B1 (SmCB1; also known as Sm31), the
mature form of which has a molecular mass of approxi-
mately 31 kDa, is highly antigenic during schistosome
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Page 2 of 11infection, both in human patients [24-26] and in experi-
mentally infected mice [27]. Thus we hypothesized that
the 31 kDa species recognized by the pre-patent response
shown in Figure 1 corresponded to SmCB1. To test this
hypothesis, we tested plasma samples from infected mice
for the presence of SmCB1-specific antibodies by ELISA,
using recombinant, non-glycosylated SmCB1 as antigen.
Using this more sensitive technique, SmCB1-specific IgM
was detectable in plasma as early as 2 weeks post infection
(Figure 2A). Isotype class-switching of the anti-SmCB1
response became apparent at 3 weeks post infection, when
SmCB1-specific IgG1 antibodies were first detected in
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Figure 1 IgG1 elicited during pre-patent schistosome infection is primarily specific for antigens of 31 kDa. Worm antigen-specific IgM (A),
IgG1 (B) and IgG2b (C) in the plasma of wild type mice with pre-patent (2, 3 and 4 weeks post infection) and patent infection (8 weeks post infection)
were quantified by ELISA. Data are displayed as relative fluorescence units (RFU). P values for the first time points to show significant increases in
antibody level are shown (obtained by Dunn’s post-test following Kruskal-Wallis test). Experimental groups consisted of five mice per group. Data are
representative of three independent experiments. Triplicate samples of two different SWAP preparations were separated by SDS-PAGE and probed by
immunoblotting with plasma from infected mice at 2 (D), 3 (E), 4 (F) and 5 (G) weeks post infection. Bound IgG1 was detected with an alkaline
phosphatase-conjugated goat anti-mouse IgG1 antibody. H, SDS-PAGE of three SWAP samples, stained for total protein by Coomassie Blue staining.
Positions of protein molecular weight markers are indicated in kDa. Data are representative of three independent experiments.
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Page 3 of 11plasma (Figure 2B). By 4 weeks post infection, SmCB1-spe-
cific IgG2b (Figure 2C) and, unexpectedly, IgE (Figure 2D)
antibodies were also detectable. These data indicate that
the SmCB1 protein is a target of humoral responses during
pre-patent schistosome infection. Furthermore, detection
of class-switching in the response to the SmCB1 protein
suggests that a CD4
+ T helper response to SmCB1 is
mounted in parallel with the antibody response, as isotype
switching requires cognate T cell help [22]. Finally, the
detection of SmCB1-specific IgG1 (Figure 2B) and espe-
cially IgE (Figure 2D) suggests that SmCB1-specific CD4
+
T cells produce IL-4, as B cell class-switching to produc-
tion of these isotypes requires cognate T cell help from IL-
4-producing CD4
+ T cells [28].
Rapid induction of SmCB1-specific IgE in the absence of
schistosome eggs
While previous reports suggested that CD4
+ Tc e l l s
primarily mount Th1 responses to worm antigens dur-
ing pre-patent infection [7,13], we recently showed
that schistosome worms also induce IL-4-producing
CD4
+ T cells during pre-patent infection, which could
therefore serve as a source of Th2 help for the IgE
response demonstrated in Figure 2. Alternatively, Th2
polarization of the CD4
+ Tc e l lr e s p o n s et oS m C B 1
could be the result of unexpectedly early oviposition,
as schistosome eggs and egg antigens are potent,
autonomous inducers of Th2 responses that could bias
concomitant responses to wor ma n t i g e n s .T ot e s tt h i s
latter hypothesis, we examined IgE responses in mice
infected with only male or female worms, thus pre-
cluding any possibility that the animals were exposed
to eggs. Infection with either male or female worms
alone both induced significant increases in total plasma
IgE concentrations by 4 weeks post infection, with
male-only infections inducing more IgE than female
worms (Figure 3A). Furthermore, male-only and
female-only infections also induced SmCB1-specific
IgE responses by 4 weeks post infection, with males
again inducing more IgE than females (Figure 3B).
Thus, exposure to either male or female worms was
sufficient for rapid induction of total and antigen-spe-
cific IgE. The results also demonstrate that total and
SmCB1-specific IgE responses are not induced as a
result of early oviposition. That male worms induced
more total and SmCB1-specific IgE than did female
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Figure 2 Relative concentrations of SmCB1-specific immunoglobulin isotypes in plasma of mice with pre-patent schistosome infection.
SmCB1-specific IgM (A), IgG1 (B), IgG2b (C) and IgE (D) in the plasma of wild type mice with pre-patent (2, 3 and 4 weeks post infection) and
patent infection (8 weeks post infection) were quantified by ELISA. Data are displayed as relative fluorescence units (RFU) for IgM (A), IgG1 (B)
and IgG2b (C), and as relative absorbance units (RAU) for IgE (D). P values for the first time points to show significant increases in antibody level
are shown (obtained by Dunn’s post-test following Kruskal-Wallis test). Experimental groups consisted of five mice per group. Data are
representative of three independent experiments.
de Oliveira Fraga et al. BMC Immunology 2010, 11:56
http://www.biomedcentral.com/1471-2172/11/56
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female worms in the absence of males [29].
T cell help and IL-4 are required for SmCB1-specific IgE
production during pre-patent infection
To test whether worm-induced pre-patent Th2
responses, such as the those we have described
recently [14], are involved in class-switching of the
anti-SmCB1 response to IgE, we tested whether the
SmCB1-specific IgE response was dependent on CD4
+
T cell help and IL-4. First, we examined worm-induced
IgE responses in mice where provision of CD4
+ T cell
help to B cells is prevented through disruption of
MHC II gene expression. Consistent with a role for
CD4
+ T cell help in the SmCB1-specific IgE response,
SmCB1-specific IgE antibodies were not detected in
the plasma of infected MHC II
-/- mice (Figure 4A),
despite the fact these animals express constitutively
high levels of nonspecific natural IgE [14,30]. Second,
to test the role of IL-4 in the generation of SmCB1-
specific IgE, IL-4 activity was blocked in vivo by
administration of a neutralizing anti-IL-4 monoclonal
antibody. Neutralization of IL-4 completely ablated the
production of both total (Figure 4B) and SmCB1-speci-
fic IgE (Figure 4C) at 4 weeks post infection, demon-
strating that these responses require IL-4. In contrast
levels of SmCB1-specific IgG1 and IgG2b were either
not affected or augmented by anti-IL-4 treatment (Fig-
ure 4D), demonstrating that this treatment did not
result in a general impairment of B cell responses.
Together, these data suggest that the SmCB1-specific
IgE response during pre-patent infection is dependent
on a concomitant IL-4-producing CD4
+ Th e l p e r
response to worm antigens.
Natural human exposure to schistosome worms induces
IgE responses to SmCB1
As SmCB1 appears to be a potent inducer of antigen-
specific IgE responses in infected mice before the onset
of egg production, we questioned whether similar
responses were induced in humans exposed to schisto-
some infection. Because human cases of acute schisto-
some infection, prior to the onset of oviposition, are
rarely detected, we chose instead to analyze a cohort of
egg-negative or putatively resistant (also known as
“endemic normal”) Brazilian subjects, who are exposed
to schistosome worm antigens but presumably do not
experience high levels of egg antigens, as they never
show evidence of active, patent infection, i.e. parasite
eggs are not detectable in the stool and egg-induced
pathology does not develop [2]. Sera from endemic nor-
mal subjects contained IgE antibodies specific for SWAP
and SmCB1 (Figure 5A), suggesting that, as in mice,
human exposure to schistosome worms is sufficient to
induce antigen-specific IgE, in the absence of substantial
exposure to eggs. Indeed, endemic normal patients
exhibited significantly higher levels of SmCB1-specific
IgE than did susceptible subjects who experience patent
schistosome infections (Figure 5A). In contrast, patients
with a history of patent infection exhibited higher levels
of SWAP-specific IgG4 than did endemic normal sub-
jects, consistent with the association of IgG4 antibodies
with chronic patent schistosomiasis [31].
Discussion
The haploid genomes of the Schistosoma contain
upwards of 3.6 × 10
8 base pairs and are predicted to
encode for 12,000 or more genes [32]. While not all
these genes are expressed during the intramammalian
A
0
250
500
750
1000
1250
P<0.01
P<0.001
I
g
E
 
c
o
n
c
.
 
(
n
g
/
m
l
)
B
R
A
U
0
5
10
15
20
25
30
Non-infected
female
male
mixed
Non-infected
female
male
mixed
P<0.001
P<0.05
P<0.02
P<0.02
P<0.002
P<0.05
Figure 3 IgE responses to worm antigens are independent of schistosome eggs. Concentrations of total (A) and SmCB1-specific IgE (B) in
plasma of mice infected for 4 weeks with female, male or mixed sex infections were determined by ELISA. P values were calculated by Dunn’s
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Page 5 of 11phase of the life cycle [33], it is nonetheless unexpected
that such an apparently limited number of gene pro-
ducts are recognized by the host immune system after 4
weeks of exposure to the developing worms. While other
protein species are clearly targeted by the humoral
response during pre-patent infection [34], (Figure 1G),
our data suggest that the majority of the antigen-specific
antibodies produced during the first five weeks of infec-
tion target an antigen of approximately 31 kDa. While we
cannot exclude the possibility that other protein species
are responsible for some of the reactivity in the 31 kDa
band, the data in Figure 2 indicate that SmCB1, a known
immunogenic protein of 31 kDa molecular mass (in the
mature form, [24,35]), is the target of a robust humoral
response during the first four weeks of infection. Further-
more, the appearance of SmCB1-specific antibodies at
two weeks post infection and the subsequent amplifica-
tion and class-switching of the response over the follow-
ing weeks correlates with the known temporal expression
pattern of SmCB1. Performing a central nutritive func-
tion in the degradation of host proteins within the para-
site gut [23], SmCB1 expression is detectable in cercariae
[36] and newly transformed schistosomula [37]and is
maintained into adulthood [38,39].
While it is tempting to speculate that immune eva-
sion mechanisms employed by the parasite to minimize
immune recognition, such as molecular camouflage
and mimicry, are factors in limiting the number of
antigens to which responses are detected, other
mechanisms may contribute to focus the adaptive
response on SmCB1. First, the schistosome regularly
regurgitates its gut contents, including SmCB1, making
the protein available for interaction with the immune
system. Second, the potentially inflammatory remains
of regurgitated host cells [40] may act as an adjuvant
for the comingled SmCB1 when it is encountered by
antigen-presenting cells. Finally, recent findings have
suggested that cysteine protease activities present
immunostimulatory molecular motifs, akin to toll-like
receptor ligands such as lipopolysaccharide, but which
preferentially initiate Th2 responses rather than Th1
responses [41]. Because vertebrates do not secrete
cysteine proteases [42], it is hypothesized that the ver-
tebrate immune system has evolved sensors for the
presence of cysteine proteases in extracellular spaces
and interprets their presence as a “danger signal”.T h i s
mechanism may explain the Th2 priming properties of
helminths and allergens, as significant cysteine pro-
tease activity is frequently associated with these two
classes of immunostimulatory agents [43].
In other pathogens, focused responses to immunodo-
minant antigens contribute to pathogen persistence
and transmission. For example, in viruses capable of
rapid genetic change, such as retroviruses [44],
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Page 6 of 11orthomyxoviruses [45] andh e p a d n a v i r u s e s[ 4 6 ] ,
responses to immunodominant epitopes can select for
escape mutants that avoid immune killing, resulting in
viral persistence and transmission to new hosts. In
more complex eukaryotic pathogens such as Trypano-
soma, narrowly focused responses to immunodominant
antigens, such as the variant surface glycoproteins of
African trypanosomes [47] and members of the highly
diverse trans-sialidase gene family of T. cruzi [48], pro-
vide the parasites with a mechanism for immune eva-
sion through antigenic variation. In Toxoplasma
gondii, extreme focusing of the immune response on
certain immunodominant members of the SRS (SAG1-
related sequences) family of surface antigens may pro-
mote parasite survival by distracting the host response
away from other epitopes [49]. Focused immune
responses to immunodominant antigens can therefore
confer survival and transmission advantages, resulting
in selection for and conservation of immunodominant
antigens in a wide variety of unrelated pathogens. It is
tempting to speculate that SmCB1 serves a similar
function for schistosomes by inducing responses that
are advantageous to the parasite, perhaps by stimulat-
ing CD4
+ T cell responses that provide essential sig-
nals for parasite development [4,50]. The possibility
that secreted parasite proteases may have functions
that extend beyond their nutritive role warrants further
investigation. Indeed, schistosomes are known to
release catalytically inactive forms of proteases [51,52],
with amino acid sequences that are almost identical to
the active forms, suggesting these molecules have func-
t i o n sd i s t i n c tf r o mh o s tp r o t e i nd e g r a d a t i o n .
While schistosome eggs are thought to be the major sti-
mulus for Th2 response induction during schistosome
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Figure 5 IgE responses to SmCB1 in exposed human subjects. Archived sera obtained from egg-positive and egg-negative (i.e. putatively
resistant) subjects at the time of enrollment were assayed for IgE (A) and IgG4 responses (B) to SWAP and SmCB1 by ELISA. Boxes show the
interquartile range and the median values obtained. Whiskers indicate the ranges of the data. P values were calculated by Dunn’s post-test
following Kruskal-Wallis test. Number of individuals in each group: egg-positive (n = 13) egg-negative (n = 8).
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worms induce type 2 responses before oviposition begins
[14]. By showing here that in vivo ablation of cognate T
cell help or blockade of IL-4 signaling both prevented the
pre-patent SmCB1-specific IgE response, our data suggest
that the pre-patent Th2 response to worms is functional
and provides help for humoral responses to antigens such
as SmCB1. Interestingly, Th2 response induction by pre-
patent schistosome infection has been documented pre-
viously. Exposure of mice and humans to cercariae of the
avian schistosome Trichobilharzia regenti, which does not
result in patent infection, also results in induction of IgE
responses and sensitization of basophils to produce IL-4
[53]. Whether pre-patent Th2 responses influence the
development of subsequent Th2 responses to schistosome
eggs remains to be tested, but the hypothesis that pre-
patent infection primes the subsequent anti-egg response
has been proposed by others [54].
Our analysis of sera from human subjects exposed to
schistosome infection demonstrates that SmCB1 is also
the target of an IgE response in humans. That puta-
tively resistant individuals exhibit significantly higher
levels of SmCB1-specific IgE than infected subjects
agrees with various other data that implicate parasite-
specific IgE in mediating protective functions upon
exposure to schistosome infection [31,55]. For exam-
ple, high levels of specific IgE correlate with acquisi-
tion of resistance to re-infection in humans [56] and
specific IgE is suspected to mediate parasite killing in
some laboratory animal models of schistosome infec-
tion [57]. However, resistance in well-defined cohorts
of putatively resistant Brazilian subjects is thought to
be mediated by Th1 responses to worm antigens [58],
similar to the immunity induced in mice by exposure
to irradiated cercariae [59]. An alternative explanation
for our finding is that persistent IL-10 production in
chronically infected individuals leads to diminished IgE
production and elevated IgG4 titers [60]. In this case,
high SmCB1-specific IgE levels in putatively resistant
subjects could be explainedb yt h ea b s e n c eo fc h r o n i c
infection in these individuals. On the other hand, there
is evidence that responses to certain antigens, such as
the S. mansoni tetraspanins TSP-1 and TSP-2, may
contribute to resistance in putatively resistant subjects
[61], so the role of SmCB1 as a protective antigen may
warrant further investigation. It is plausible that a pro-
tease with significant nutritive function that is
expressed from the very beginning of infection may be
a target of protective immune responses. Immune
responses to another worm protease, calpain, can med-
iate significant resistance to challenge infection [62]
suggesting that proteases are viable targets for future
vaccines.
Conclusions
In conclusion, our data suggest that SmCB1 is an
immunodominant target of the immune response during
pre-patent schistosome infection and that the response
to this cysteine protease exhibits hallmarks of a Th2
response. These findings suggest that, in addition to the
nutritive function associated with its proteolytic activity,
SmCB1 may serve in an immunological capacity to
induce responses that influence the outcome of schisto-
some infection. Modulation of immune responses to
proteases might therefore impede the establishment of
schistosome infections and represent a novel approach
to the treatment and/or prophylaxis of schistosomiasis.
Methods
Animals and parasites
Wild type C57BL/6 and C57BL/6 MHC II
-/- mice were
purchased from National Cancer Institute (Frederick,
MD) and Taconic (Hudson, NY) respectively, and main-
tained in a specific pathogen-free environment. Mixed
male and female cercariae of Schistosoma mansoni
(Puerto Rican strain) were obtained from infected Biom-
phalaria glabrata snails provided by Dr. Fred Lewis
(BRI, Rockville, MD). To obtain separate male and
female cercariae, individual B. glabrata snails were
exposed to single miracidia and tested for cercarial pro-
duction 4-6 weeks later. Mice were infected by immer-
sion of the tail for 40 min in water containing 50-150 S.
mansoni cercariae and were sacrificed 1-8 weeks later,
depending on experiment. For plasma isolation, blood
was obtained by cardiac puncture at euthanasia, col-
lected into heparinized tubes and centrifuged at 3,300 ×
g to remove cells. In IL-4 neutralization experiments,
mice were treated twice weekly with 1 mg of the neutra-
lizing anti-mouse IL-4 antibody 11B11 administered by
intraperitoneal injection, while control groups received
control rat IgG or PBS. For preparation of schistosome
worm antigen (SWAP), adult S. mansoni were perfused
from the portal veins of infected mice and homogenized
in PBS on ice. Insoluble material was removed by centri-
fugation at 16,100 × g f o r3 0m i na t4 ° Ca n dt h er e s u l t -
ing supernatant stored at -80°C after filter sterilization
and determination of protein concentration by Bradford
assay. In all experiments, experimental groups of mice
were exposed at the same time to parasites from the
same cercarial pool. All studies involving animals were
performed in accordance with protocols approved by
the USUHS Institutional Animal Care and Use Commit-
tee and included 5-10 mice in each group.
ELISA quantification of mouse immunoglobulin isotypes
For detection of SWAP- and SmCB1-specific IgM, IgG1,
IgG2b and IgA, 4HBX plates (Immulon Thermo, MA)
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(5 μg/ml) in borate buffered saline (BBS) for 2 hours at
room temperature (RT). After 5 washes and blocking
with BBS containing 1% of fetal calf serum (FCS), the
immune plasma were diluted in BBS (1:4, the optimal
dilution resulting in the highest signal-to-noise ratio
determined for each isotype beforehand) containing
0.02% Tween 20 (BBST; Sigma, St Louis, MO) and
applied to the plates for 2 hours at RT. For isotypes
other than IgE, the plates were incubated with alkaline
phosphatase-conjugated goat antibodies against mouse
IgM, IgG1, IgG2b, or IgA (Southern Biotechnology
Associates) diluted 1:1000 in BBST for 30 minutes at
RT and then washed 10 times. The reaction was devel-
oped by addition of 4- methylumbelliferyl phosphate
substrate (4-MUP; Sigma). Fluorescence was detected on
a SPECTRAmax M2 microplate fluorometer (Molecular
Devices, Sunnyvale, CA) at excitation and emission
wavelengths of 360nm and 449 nm, respectively. Detec-
tion of SmCB1-specific IgE was the same as for other
isotypes, except that mice were infected specifically for
IgE investigations and IgG was first adsorbed by incu-
bating plasma samples with GammaBind G Sepharose
(Amersham Biosciences, Uppsala, Sweden) overnight at
4°C prior to application to the assay plates. After washes
and incubation with alkaline phosphatase-conjugated
goat anti-mouse IgE (BD Biosciences, San Diego, CA),
the reaction was developed by addition of p-nitrophenyl
phosphate disodium salt substrate (PNPP; Pierce, Rock-
ford, IL), stopped with 2 N NaOH and absorbance mea-
sured at 405 nm. Concentrations of total IgE were
determined using a sandwich ELISA kit (Antibody Set
for mouse IgE; BD Biosciences), according to the manu-
facturer’s instructions.
Immunoblotting
Preparations of SWAP (15 μg/lane) were separated by
SDS-PAGE on 12% Bis-Tris gels under reducing condi-
tions, transferred to PVDF membranes and probed with
plasma from infected mice at 1:500 dilution. Bound anti-
bodies were detected using alkaline phosphatase-conju-
gated goat antibodies against mouse IgM, IgG1, IgG2b
and IgA (Southern Biotechnology Associates, Birming-
ham, AL) diluted 1:1000, in conjunction with a chemilu-
minescent immunodetection system (WesternBreeze;
Invitrogen, Carlsbad, CA).
Recombinant S. mansoni cathepsin B1 (SmB1)
The original DNA plasmid construct used to produce a
recombinant pro-form of the S. mansoni cathepsin B1
(SmCB1, a.k.a. Sm31) cysteine protease in Pichia pas-
toris [63] was subjected to PCR-based site-directed
mutagenesis in order to remove a putative glycosylation
site. Specifically, threonine residues at positions 185 and
300 (see Genbank accession number AJ506157) were
substituted for alanines. Otherwise, expression of the
protein was as previously described [63]. Yeast-
expressed SmCB1 was lyophilized in sodium phosphate
buffer 0.05 M, pH 6.0 for storage and solubilized at a
concentration of 2.4 mg/ml prior to use.
Human subjects
Sera from human subjects residing in endemic areas
near Governador Valadares, Minas Gerais State, in
southeast Brazil, were analyzed anonymously for anti-
body isotype responses to SWAP and SmCB1. Archived
sera were randomly selected from two groups of sub-
jects characterized as either egg-positive or egg-negative
according to semi-annual feces examination from 1997
to the present. Egg-positive subjects were defined as
those that have tested positive for the presence of S.
mansoni eggs in their feces on at least one occasion
since monitoring began in 1997. All patients in this
group are treated with praziquantel when a schistosome
infection is detected, and some individuals have experi-
enced multiple episodes of re-infection and treatment.
Egg-negative ("endemic normal”) subjects were defined
as individuals that reside in areas of known transmission
but who have (i) never tested positive for schistosome
eggs on fecal examination since monitoring began in
1997 and (ii) have no known history of schistosome
infection or praziquantel treatment. Antibody responses
to SWAP and SmCB1 at the time of enrollment in
1997/1998 were assessed by ELISA analysis of archived
sera as described above for murine immunoglobulins,
except that alkaline phosphatase-conjugated mouse anti-
human IgG4 (BD Pharmingen, BD Biosciences, San
Diego, CA) and goat anti-human IgE (Biosource, Camar-
illo, CA) were used as secondary reagents. Assays were
developed by addition of PNPP, stopped with 2 N
NaOH and absorbance measured at 405 nm. All studies
involving human subjects were conducted under the
auspices of UNIVALE and were approved by the rele-
vant ethics committees (UNIVALE, protocol PQ 015/
07-4, approved 04 December, 2007; CONEP (Brasilia),
Registration: 14004, protocol number 25000.078835/
2007-81, approved 12 July, 2007). Written informed
consent was obtained from all participating subjects and
is maintained on file at UNIVALE.
Statistical analyses
Because unequal variances between experimental
groups were frequently encountered in some experi-
ments, stringent non-parametric tests were used
throughout to test the significance of differences
between experimental groups. For comparison of two
groups, significance was tested using Mann-Whitney
tests, and for experiments involving three groups or
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Page 9 of 11more, the significance of differences was tested using
Kruskal-Wallis tests followed by Dunn’sm u l t i p l ec o m -
parison tests. Statistical analyses were performed with
GraphPad Prism Version 4.0 software (GraphPad Soft-
w a r e ,I n c . ,S a nD i e g o ,C A ) .Pv a l u e so fl e s st h a n0 . 0 5
were considered significant. Data are expressed as
mean value ± SEM. All data are representative of at
least two independent experiments.
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